L

Longeveron Inc. (LGVN)

NCM – Real vaqt narxi. Valyuta: USD

0.75

-0.09 (-10.48%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

L

Longeveron Inc. (LGVN)

NCM – Real vaqt narxi. Valyuta: USD

0.75

-0.09 (-10.48%)

Yopilishda: May 12, 2026, 4:00 PM EDT

11.05.2026

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication DMC performed a risk-benefit assessment, identified no new safety concerns, and recommended continuation of the study as designed through completion This review represents the final planned independent safety assessment prior to completion of the trial ELPIS II top-line trial results anticipated in August 2026 MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the independent Data Monitoring Committee (DMC) has completed its final prespecified data review for the ongoing, fully enrolled, Phase 2b clinical trial (ELPIS II) evaluating laromestrocel (Lomecel-B®) as a potential adjunct therapy for hypoplastic left heart syndrome (HLHS). The DMC based its review on available data for all participating patients enrolled.

08.05.2026

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that a constructive Type C meeting with the U.S. Food and Drug Administration (FDA or Agency) was held in late March, with the FDA providing their meeting summary in late April, to discuss the ongoing development of laromestrocel (LOMECEL-B®), a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase 2b clinical trial (ELPIS II) for hypoplastic left heart syndrome (HLHS). Top-line results from the randomized, controlled Phase 2b ELPIS II clinical trial are anticipated in August 2026.

05.05.2026

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m.

08.04.2026

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs).

17.03.2026

Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript

17.03.2026

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Longeveron reported financial results for the year ended December 31, 2025 and provided a business update. Results from pivotal P2 trial anticipated 3Q26.

17.03.2026

Longeveron Braces For Q4 Results Following Recent Funding Boost

Tuesday's move higher precedes an earnings print where analysts are looking for an EPS loss of 38 cents on estimated revenue of $106,200. This revenue target represents a sharp decline from the $603,000 reported in the year ago quarter.

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication DMC performed a risk-benefit assessment, identified no new safety concerns, and recommended continuation of the study as designed through completion This review represents the final planned independent safety assessment prior to completion of the trial ELPIS II top-line trial results anticipated in August 2026 MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the independent Data Monitoring Committee (DMC) has completed its final prespecified data review for the ongoing, fully enrolled, Phase 2b clinical trial (ELPIS II) evaluating laromestrocel (Lomecel-B®) as a potential adjunct therapy for hypoplastic left heart syndrome (HLHS). The DMC based its review on available data for all participating patients enrolled.

08.05.2026

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that a constructive Type C meeting with the U.S. Food and Drug Administration (FDA or Agency) was held in late March, with the FDA providing their meeting summary in late April, to discuss the ongoing development of laromestrocel (LOMECEL-B®), a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase 2b clinical trial (ELPIS II) for hypoplastic left heart syndrome (HLHS). Top-line results from the randomized, controlled Phase 2b ELPIS II clinical trial are anticipated in August 2026.

08.04.2026

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs).

17.03.2026

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Longeveron reported financial results for the year ended December 31, 2025 and provided a business update. Results from pivotal P2 trial anticipated 3Q26.

Search stocks

Longeveron Inc. (LGVN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Longeveron Inc. (LGVN)

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Longeveron Braces For Q4 Results Following Recent Funding Boost

Videolar

No Data

Press-relizlar

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update